Ronald Blue & Co’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q2
$931K Sell
7,037
-743
-10% -$94.8K 0.03% 78
2017
Q1
$969K Sell
7,780
-290
-4% -$34.6K 0.03% 78
2016
Q4
$931K Buy
8,070
+325
+4% +$37.5K 0.04% 83
2016
Q3
$915K Sell
7,745
-390
-5% -$47.3K 0.04% 73
2016
Q2
$987K Buy
8,135
+1,629
+25% +$185K 0.05% 67
2016
Q1
$704K Sell
6,506
-178
-3% -$18.4K 0.04% 70
2015
Q4
$686K Sell
6,684
-8,758
-57% -$881K 0.04% 76
2015
Q3
$1.44M Sell
15,442
-5,713
-27% -$553K 0.08% 53
2015
Q2
$2.06M Sell
21,155
-366
-2% -$36.7K 0.1% 37
2015
Q1
$2.17M Sell
21,521
-4,047
-16% -$412K 0.1% 35
2014
Q4
$2.67M Sell
25,568
-464
-2% -$48.9K 0.13% 32
2014
Q3
$2.77M Buy
26,032
+961
+4% +$99.7K 0.18% 25
2014
Q2
$2.62M Sell
25,071
-49
-0.2% -$4.95K 0.17% 25
2014
Q1
$2.47M Buy
25,120
+324
+1% +$30K 0.18% 28
2013
Q4
$2.27M Sell
24,796
-1,603
-6% -$148K 0.17% 33
2013
Q3
$2.29M Buy
26,399
+16,805
+175% +$1.51M 0.19% 29
2013
Q2
$824K Buy
+9,594
New +$814K 0.07% 46

Other funds holding JNJ

Ronald Blue & Co's JNJ Position: Q2 2017 in Review

Ronald Blue & Co reduced its Johnson & Johnson (JNJ) stake by 9.6% in Q2 2017, selling an estimated $94.8K and leaving 7,037 shares worth $931K. The position accounts for 0.03% of the portfolio, ranked #78.

Ronald Blue & Co first reported a position in JNJ in Q2 2013 and has held it in 17 quarters since. The position peaked at $2.77M in Q3 2014. 2,350 funds tracked by Wall St. Rank hold JNJ as of Q2 2017.

  • Ronald Blue & Co held 7,037 shares of Johnson & Johnson worth $931K as of Q2 2017.
  • Ronald Blue & Co sold 743 Johnson & Johnson shares in Q2 2017, an estimated $94.8K.
  • Johnson & Johnson made up 0.03% of Ronald Blue & Co's portfolio in Q2 2017, its #78 holding.
  • Ronald Blue & Co first reported a position in Johnson & Johnson in Q2 2013 and has held it in 17 quarters since.
  • Ronald Blue & Co's Johnson & Johnson position peaked at $2.77M in Q3 2014.
  • 2,350 funds tracked by Wall St. Rank held Johnson & Johnson as of Q2 2017.

Based on Ronald Blue & Co's 13F filing for Q2 2017, filed 28 Jul 2017.